The rhesus incompatible pregnancy and its consequences for affected fetuses and neonates

Neonatal/perinatal diagnosis of hemolysis using ETCOc

Hemolysis is a pathological shortening of the red blood cell lifespan. When hemolysis occurs in a neonate, hazardous hyperbilirubinemia and severe anemia could result. Hemolysis can be diagnosed, and its severity quantified, by the non-invasive measurement of carbon monoxide (CO) in exhaled breath. The point-of-care measurement is called "End-tidal CO corrected for ambient CO" (ETCOc). Herein we explain how ETCOc measurements can be used to diagnose and manage various perinatal/neonatal hemolytic disorders. We provide information regarding five clinical situations; 1) facilitating a precise diagnosis among neonates presenting with anemia or jaundice of unknown etiology, 2) monitoring fetal hemolysis with serial measurements of mothers during pregnancy, 3) measuring the duration of hemolysis in neonates with hemolytic disease, 4) measuring neonates who require phototherapy, to determine whether they have hemolytic vs. non-hemolytic jaundice, and 5) measuring all neonates in the birth hospital as part of a jaundice-detection and management program.

Knowledge about Rh-incompatibility and its associated factors among antenatal care recipients in public hospitals of Wolaita zone, 2022: facility-based cross-sectional study

Background

Lack of awareness about the Rh-incompatibility problem is one of the factors hindering early prevention in Ethiopia. Thus, the objective of this study is to determine what was known about Rh-incompatibility disorders and their associated factors among pregnant women participating in prenatal care in southern Ethiopia.

Design setting and participants

A facility-based cross-sectional study was employed in four selected hospitals during 1-30 August 2022. The systematic random sampling method was used as a technique of selecting the study participants. The study was performed using a structured questionnaire. The data were coded and entered into EPI DATA V.4.6, and then the analysis was done using SPSS V.23 software program. Adjusted OR with 95% CI was the measurement unit of association between independent variables and outcome variables. The significance level was established as p<0.05.

Result

414 women took the survey, which corresponds to a response rate of 98.1%. Of those who responded, only 48% knew their blood group. The study found that 35.3% (95% CI: 31% to 40%) of women had a good knowledge of Rh-incompatibility. Maternal educational level above secondary school, multigravida women, blood type screening in the maternity ward, early counselling on Rh status and Rh-incompatibility and a positive attitude among women were significantly associated with pregnant women's knowledge of Rh-incompatibility.

Conclusion

The majority of pregnant women had poor knowledge regarding Rh-incompatibility. Therefore, all responsible organisations should focus on expanding pregnant women's knowledge of Rh-incompatibility and the factors significantly associated with knowledge of Rh-incompatibility.

Case report: Double filtration plasmapheresis (DFPP) for severe rhesus-D alloimmunization in two pregnant patients

Maternal erythrocyte alloimmunization is one of the most important causes of fetal anemia. The standard treatment for anemic fetuses is intrauterine blood transfusion (IUT). However, IUT may have adverse effects, particularly before 20 weeks of gestation. In this report, two women who had previously had severely affected alloimmunized pregnancy developed high titers of anti-D antibodies before 20 weeks of gestation. Ultrasound Doppler showed severe fetal anemia, and intrauterine transfusion was expected to be unavoidable. To prolong pregnancy to a gestation in which intravascular IUT was possible, we used repeated double filtration plasmapheresis (DFPP) as a rescue therapy. The titers of IgG-D, IgG-A, and IgG-B decreased after DFPP treatment. One woman successfully prolonged pregnancy until 20 weeks of gestation. Subsequently, she underwent four cycles of IUTs and delivered at 30 weeks of gestation by emergency cesarean section due to fetal bradycardia during the fifth intrauterine transfusion. The other woman successfully delayed intrauterine transfusion until 26 weeks of gestation. The favorable results of the two patients indicate that DFPP may be an effective and safe treatment modality for RhD immunity in pregnant women. Moreover, DFPP is potentially helpful for reducing the occurrence of ABO hemolytic disease in neonates due to the clearance of IgG-A and IgG-B antibodies (e.g., O pregnant women harbored A/B/AB neonates). However, more clinical trials are needed to verify the results.

Retrospective Analysis of the Development of Human Thyroglobulin during Pregnancy in Patients with Treated Non-Recurrent Differentiated Thyroid Cancer

Aim: Therapy success in patients with differentiated thyroid cancer (DTC) after thyroidectomy and radioiodine therapy (RIT) is proven by permanent decrease in human thyroglobulin (hTg) to <1 ng/mL. In this retrospective analysis hTg development before, during and after pregnancy were analyzed. Material and methods: A descriptive analysis of hTg courses in 47 women with 57 pregnancies under levothyroxine substitution was performed after treatment of DTC without evidence of residual or recurrent disease. We compared hTg levels before, during and after pregnancies. A median of four measurements were performed during pregnancy. Results: In five out of the 47 patients at least one hTg increase to ≥1.0 ng/mL occurred during pregnancy (P1: 1.1; P2: 1.75; P3: 1.0; P4: 1.1; P5: 1.07 ng/mL). In another three cases an increase to ≥0.5 ng/mL occurred. After delivery, all patients returned to undetectable hTg levels. Human Tg maxima during pregnancy were significantly elevated according to Friedman´s Chi2 and p Holm−Bonferroni. Conclusion: In women with ablative thyroid therapy after DTC, a temporary elevation in hTg levels during pregnancy may occur. The reason therefore remains unclear and requires further investigation.